Protective effects of exogenous fructose-1,6-biphosphate during small bowel transplantation in rats.
BACKGROUND
We assessed the effect of adding exogenous fructose-1,6-biphosphate (F16BP) to the preservation solution (University of Wisconsin storage solution) used during an experimental procedure of small bowel transplantation in rats.


METHODS
We studied levels of the nucleotides hypoxanthine/xanthine and adenosine in tissue after cold ischemia, as well as histologic changes and associated deleterious processes such as bacterial translocation produced by the reperfusion associated with the transplantation.


RESULTS
The groups of rats treated with F16BP showed the lowest levels of hypoxanthine/xanthine and uric acid, the highest levels of adenosine, and the lowest levels of histologic damage and lactate dehydrogenase release to the bloodstream. Consumption of intestinal hypoxanthine during reperfusion was lowest in the groups treated with F16BP, as was the incidence of bacterial translocation.


CONCLUSIONS
This study shows a protective effect of exogenous F16BP added to University of Wisconsin solution during experimental intestinal transplantation in rats. This protective effect, reflected by decreased intestinal damage and bacterial translocation, was related to a decrease in adenosine triphosphate depletion during cold ischemia before intestinal transplantation, and to the reduced availability of xanthine oxidase substrates for free radical generation during reperfusion.
Sola
Anna
A
Department of Medical Bioanalysis, Instituto de Investigaciones Biomédicas, IIBB-CSIC, IDIBAPS, Barcelona, Spain.
De Oca
Javier
J
Alfaro
Vicente
V
Xaus
Carme
C
Jaurrieta
Eduardo
E
Hotter
Georgina
G
D000241:Adenosine / Q000378:metabolism / Q000494:pharmacology; D000255:Adenosine Triphosphate / Q000378:metabolism; D000493:Allopurinol / Q000494:pharmacology; D000818:Animals; D018988:Bacterial Translocation / Q000187:drug effects; D015925:Cryopreservation; D019610:Cytoprotection; D005635:Fructosediphosphates / Q000494:pharmacology*; D005978:Glutathione / Q000494:pharmacology; D019271:Hypoxanthine / Q000378:metabolism; D007328:Insulin / Q000494:pharmacology; D007421:Intestine, Small / Q000187:drug effects* / Q000378:metabolism / Q000473:pathology / Q000637:transplantation*; D007422:Intestines / Q000382:microbiology; D007770:L-Lactate Dehydrogenase / Q000097:blood; D008297:Male; D019188:Organ Preservation Solutions / Q000494:pharmacology; D018384:Oxidative Stress; D011887:Raffinose / Q000494:pharmacology; D051381:Rats; D017207:Rats, Sprague-Dawley; D015427:Reperfusion Injury / Q000378:metabolism; D014527:Uric Acid / Q000378:metabolism; D019820:Xanthine / Q000378:metabolism
D005635:Fructosediphosphates; D007328:Insulin; D019188:Organ Preservation Solutions; C055206:University of Wisconsin-lactobionate solution; D019820:Xanthine; D014527:Uric Acid; D019271:Hypoxanthine; D000493:Allopurinol; D000255:Adenosine Triphosphate; D007770:L-Lactate Dehydrogenase; D005978:Glutathione; D000241:Adenosine; C029063:fructose-1,6-diphosphate; D011887:Raffinose